The present technology is directed to compounds (e.g., Avermectin derivatives), compositions, and methods related to modulation of FXR. In particular the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.
